Skip to main content

Table 1 Approaches that directly target B cells and plasma cells

From: Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

Target Agent Putative/intended mechanism of action Developmental status
CD19 MD1342 (fully human) B-cell depletion Phase I for RA, trial suspended
  CD19 chimeric antigen receptors   Phase I/II for B-cell malignancies
  Blinatumomab   
  XmAb5574/MOR208   
  MEDI-551   
CD20 Rituximab (chimeric)   Approved for use in NHL, RA and ANCA vasculitides
  Ocrelizumab (humanized)   Phase III for RRMS and PPMS
  Veltuzumab (humanized)   Phase III for RA, phase I/II for AITP
  Ofatumumab (fully human)   Phase III for RA, phase I/II for RRMS
CD22 Epratuzumab (humanized) Blockade of CD22 - partial depletion of B cells, inhibition of activation, proliferation, survival of B cells Phase III for SLE
CD52 Anti-CD52 or Campath-1h, Alemtuzumab Depletion of T cells and B cells Phase III for MS, phase II for autoimmune cytopenias, phase I for inclusion body myositis, phase I/II for RA not continueda
  1. AITP, Autoimmune thrombocytopenia; ANCA, anti-neutrophil cytoplasmic antibody; MS, multiple sclerosis; NHL, non-Hodgkin lymphoma; PPMS, primary progressive multiple sclerosis; RA, rheumatoid arthritis; RRMS, relapsing/remitting multiple sclerosis; SLE, systemic lupus erythematosus. Data from http://www.clinicaltrials.gov (accessed 5 January 2012). aSee [150152].